Biodexa Pharmaceuticals releases patient updates on PFS, OS from MAGIC-1 study

Biodexa Pharmaceuticals released patient updates on progression-free survival and overall survival from the ongoing MAGIC-1 study of MTX110 in recurrent glioblastoma, a lethal form of adult brain cancer. The study is designed to evaluate the feasibility, safety and efficacy of treating rGBM patients with MTX110. The company earlier reported patients #1 and #2 in Cohort A achieved overall survival of 12 and 13 months, respectively. The remaining two patients in Cohort A remain on follow-up. Patient #3 has achieved 13 months OS to date, with six months progression free survival. Patient #4 has not progressed and achieved 12 months PFS and 12 months OS to date. Glioblastoma is the most common and lethal form of brain cancer in adults with a universally fatal prognosis, particularly when it recurs. The median survival post-recurrence is 6.5 months, making any progress toward extending patients’ lives a significant breakthrough. The new data builds on earlier promising trial results with MTX110 in Diffuse Midline Glioma, and could signal a potential shift in the standard of care. The GBM treatment market was $2.5 billion in 2022, projected to grow nearly 10 percent annually through 2030. MTX110’s value may be further enhanced by its potential in DMG, a mostly pediatric and universally fatal brain cancer.